Moreover, our previous study revealed that endostatin 33 peptide is a disintegrin α6β1 agent that exerts antitumor activity by inhibiting the PI3K-Akt signaling pathway in prostate cancer [24]. The gene discussed is AKT1; the disease is Familial prostate cancer.